Nivestim is a pharmaceutical product classified as a biosimilar filgrastim, which is a recombinant form of the human granulocyte colony-stimulating factor (G-CSF). It is primarily used to stimulate the production of white blood cells (neutrophils) in patients undergoing chemotherapy, those with chronic neutropenia, or individuals preparing for bone marrow transplantation. By boosting the neutrophil count, Nivestim effectively helps in reducing the risk of infections in patients with a compromised immune system. It is administered through subcutaneous injections or intravenous infusions, depending on the specific medical guidelines and patient needs. As a biosimilar, Nivestim offers a more cost-effective alternative to the original biologic, while maintaining similar safety, purity, and potency profiles.